Earnings Releases·Nov 10, 2026, 7:05 AM ET

908 Devices — Third Quarter 2026 Earnings Summary

Total revenue increased 35% year-over-year to $19.0 million, driven by a 46% rise in product revenue to $15.8 million and the inclusion of NIRLab revenue post-acquisition, while recurring revenue reached $5.1 million (27% of total).
Net loss from continuing operations narrowed significantly to $4.6 million from $14.9 million in the prior year, primarily due to an $11.0 million non-cash reduction in contingent consideration fair value, despite a $2.8 million increase in SG&A expenses.
Full-year 2026 revenue guidance was raised to $68.5 million–$70.0 million, reflecting 22%–25% growth over 2025, supported by a 26% year-over-year growth in the installed base to 4,409 devices and record placements of 308 units.
Balance sheet strength remains robust with $99.1 million in cash and no debt, while deferred revenue grew to $22.9 million; the acquisition of NIRLab added $10.2 million in goodwill and $44.1 million in intangible assets.